Rampart wins USPTO review on radiation protection patent claims

The USPTO issued a notice that upholds amended claims in Rampart IC’s U.S. Patent No. 11,660,056 after an ex parte reexamination initiated by Egg Medical. The decision strengthens Rampart’s IP position around lead-free radiation-shielding products used to protect clinicians and medical teams.

Why it matters: - The USPTO’s decision reinforces Rampart IC’s patent protection around radiation-shielding products used in interventional medicine. - The ruling strengthens the company’s intellectual property position after a challenge from Egg Medical. - Rampart says the upheld claims support technology designed to reduce occupational radiation exposure for clinicians and medical teams.

What happened: - Rampart IC announced that the USPTO issued a Notice of Intent to Issue an Ex Parte Reexamination Certificate for U.S. Patent No. 11,660,056. - The notice upholds the validity of the patent claims as amended. - The review followed an appeal in an ex parte reexamination initiated by Egg Medical. - The announcement was made Aug. 6, 2026, in Birmingham, Alabama.

The details: - The upheld claims continue to protect Rampart’s radiation-shielding products. - Rampart describes itself as a global leader in lead-free enhanced radiation protection devices. - CEO Tom Livingston said the outcome confirms the patentability of Rampart’s claims and validates the company’s intellectual property. - Livingston said Rampart will keep investing in technologies that improve the safety and well-being of medical professionals. - Rampart’s products are designed to support clinicians, patients and healthcare institutions. - Rampart says its solutions have been supported by two randomized controlled trials and peer-reviewed real-world evidence from more than 1,700 procedures across 150-plus sites. - The company says its solutions deliver more than 99% scatter radiation reduction and can be up to 20 times more effective than lead aprons and traditional shields. - Rampart says its products add no weight to the clinician or the procedure table. - Rampart says it is the sole worldwide manufacturer of ClearShield Technology™, a lead-free bismuth acrylic that provides consistent 1mm lead equivalency protection. - Rampart says it is the only ERPD made from completely lead-free materials. - Rampart says its products are available nationwide and through global distribution partnerships. - Rampart’s website and social channels were listed in the release, including Rampart’s LinkedIn page, Instagram account, YouTube channel and X account.

Between the lines: - The reexamination outcome gives Rampart a stronger legal foundation while the company competes in a market focused on radiation safety for medical staff. - The patent result also helps validate Rampart’s broader claim that its lead-free approach is differentiated from traditional lead-based shielding. - The company is using the ruling to underscore both product performance and commercial credibility.

What’s next: - Rampart says it will continue investing in innovation aimed at improving protection for medical professionals. - The company is likely to keep leveraging the patent outcome as support for its radiation-protection platform and product strategy.

The bottom line: - Rampart leaves the reexamination with its amended claims intact and a stronger shield around its core radiation-protection technology.